Jeito Capital closed Jeito II at more than €1bn ($1.2bn), beating its stated target and pushing the firm’s total assets under management to €1.6bn.
Compare that to Jeito I, which closed at €534m in 2021, establishing the firm’s clinical-stage, Europe-focused playbook. Jeito II doesn’t change the mandate: 15 to 20 portfolio companies, mainly in Europe, developing breakthrough therapies for severe diseases with high unmet medical needs. The larger pool means average tickets of up to €150m per company, enough to carry businesses through advanced clinical development.
Capital came from sovereign wealth funds, banks, family offices, and corporate entities across Asia, Europe, and North America. The LP base is global. Jeito II has already deployed into autoimmune, cardiometabolic, and inflammatory disease companies, as well as obesity, oncology, and reproductive medicine.
CEO Dr Rafaèle Tordjman called the close “a strong signal for European biopharma,” pointing to growing investor conviction that European companies can produce breakthrough therapies with the right financial and strategic resources.
The bet is that Europe’s clinical-stage pipeline can generate exits large enough to justify €150m-per-company exposure. Whether it can is a question Jeito won’t answer until it starts returning capital to its LPs.
Diana Kowalski